Trial · NCT05000216
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216, Phase 2, Terminated, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2025-08-22
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders. Trials, record NCT05000216. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05000216
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
- NCT number
- NCT05000216
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 258 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- First posted
- 2021-08-11
- Last updated
- 2026-06-10
- Results first posted
- 2025-08-22
- Limitations and caveats
The trial was closed prior to fully enrolling because of slow enrollment due to increasing infections in the general population with resulting elevated antibody titers, changing CDC vaccination recommendations, and vaccine hesitancy. Original enrollment goals were 60 participants per arm.
Source ClinicalTrials.gov
Registered outcomes58
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Week 4 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center (NIAID-VRC) Meso Scale Discovery (MSD) 3 plex assay (Wu-1 full-length spike, receptor binding domain (RBD), and N proteins). A threshold for achieving a protective antibody response was not established for the NIAID VRC MSD assay. The intent was to use a pre-established threshold to define a protective antibody response. However, correlates from previous studies could not be extrapolated to the CoV-2 variants circulating over the entire course of this trial. |
| Primary | Percent of Stage 2 Adult Participants Who Have a Protective Antibody Response at Week 4 | Week 4 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center (NIAID-VRC) Meso Scale Discovery (MSD) 3 plex assay (Wu-1 full-length spike, receptor binding domain (RBD), and N proteins). A threshold for achieving a protective antibody response was not established for the NIAID VRC MSD assay. The intent was to use a pre-established threshold to define a protective antibody response. However, correlates from previous studies could not be extrapolated to the CoV-2 variants circulating over the entire course of this trial. |
| Primary | Percent of Stage 2 Pediatric Participants Who Have a Protective Antibody Response at Week 4 | Week 4 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center (NIAID-VRC) Meso Scale Discovery (MSD) 3 plex assay (Wu-1 full-length spike, receptor binding domain (RBD), and N proteins). A threshold for achieving a protective antibody response was not established for the NIAID VRC MSD assay. The intent was to use a pre-established threshold to define a protective antibody response. However, correlates from previous studies could not be extrapolated to the CoV-2 variants circulating over the entire course of this trial. |
| Secondary | Percentage of Stage 1 Adult Participants Who Seroconverted | Week 4 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center Meso Scale Discovery 3 plex assay. For concentrations below the lower limit of detection (LLOD), numeric values equivalent to LLOD/2 were assigned; concentrations above the upper limit of quantification were reported without adjustments. Antibody results collected after a documented COVID-19 infection, monoclonal antibody use, or COVID-19 vaccine given off-study were excluded from the analyses. Participants missing antibody data were considered missing-completely-at-random. Seroconversion was assessed in the subgroup of participants who were anti-COVID-19 antibody negative at Week 0; defined as a result less than or equal to the positive threshold value (spike=10.8424, RBD=14.0858). Anti-COVID-19 antibody negative at Week 0 is defined separately for spike and RBD. Seroconversion was defined as having a result greater than the positive threshold at the Week 4 visit. |
| Secondary | Percentage of Stage 2 Adult Participants Who Seroconverted | Week 4 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center Meso Scale Discovery 3 plex assay. For concentrations below the lower limit of detection (LLOD), numeric values equivalent to LLOD/2 were assigned; concentrations above the upper limit of quantification were reported without adjustments. Antibody results collected after a documented COVID-19 infection, monoclonal antibody use, or COVID-19 vaccine given off-study were excluded from the analyses. Participants missing antibody data were considered missing-completely-at-random. Seroconversion was assessed in the subgroup of participants who were anti-COVID-19 antibody negative at Week 0; defined as a result less than or equal to the positive threshold value (spike=10.8424, RBD=14.0858). Anti-COVID-19 antibody negative at Week 0 is defined separately for spike and RBD. Seroconversion was defined as having a result greater than the positive threshold at the Week 4 visit. |
| Secondary | Fold Increase in Stage 1 Adult Anti-COVID-19 Antibody Levels | Week 4 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center Meso Scale Discovery 3 plex assay. For concentrations below the lower limit of detection (LLOD), numeric values equivalent to LLOD/2 were assigned; concentrations above the upper limit of quantification were reported without adjustments. Antibody results collected after a documented COVID-19 infection, monoclonal antibody use, or a COVID-19 vaccine given off-study were excluded from the analyses. Participants with missing antibody data were considered missing-completely-at-random. Fold increase was assessed in the subgroup of participants who were anti-COVID-19 antibody positive at Week 0; defined as having a result greater than the positive threshold value (spike=10.8424, RBD=14.0858). Anti-COVID-19 antibody positive at Week 0 is defined separately for spike and RBD. Fold increase = (antibody response at Week 4)/(antibody response at Week 0). |
| Secondary | Fold Increase in Stage 2 Adult Anti-COVID-19 Antibody Levels | Week 4 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center Meso Scale Discovery 3 plex assay. For concentrations below the lower limit of detection (LLOD), numeric values equivalent to LLOD/2 were assigned; concentrations above the upper limit of quantification were reported without adjustments. Antibody results collected after a documented COVID-19 infection, monoclonal antibody use, or a COVID-19 vaccine given off-study were excluded from the analyses. Participants with missing antibody data were considered missing-completely-at-random. Fold increase was assessed in the subgroup of participants who were anti-COVID-19 antibody positive at Week 0; defined as having a result greater than the positive threshold value (spike=10.8424, RBD=14.0858). Anti-COVID-19 antibody positive at Week 0 is defined separately for spike and RBD. Fold increase = (antibody response at Week 4)/(antibody response at Week 0). |
| Secondary | Change in Stage 1 Adult Anti-COVID-19 Antibody Response | Week 0 and Weeks 4 and 12 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center (NIAID-VRC) Meso Scale Discovery (MSD) 3 plex assay (Wu-1 full-length spike, receptor binding domain (RBD), and N proteins). Wu-1 full-length spike and RBD were used to assess vaccine response. For concentrations below the lower limit of detection (LLOD), numeric values equivalent to LLOD/2 were assigned; concentrations above the upper limit of quantification were reported without adjustments. Antibody results collected after a documented COVID-19 infection, monoclonal antibody use, or a COVID-19 vaccine given off-study were excluded from the analyses. Participants with missing anti-COVID-19 antibody response data were considered to be missing-completely-at-random. |
| Secondary | Change in Stage 2 Adult Anti-COVID-19 Antibody Response | Week 0 and Weeks 4 and 12 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center (NIAID-VRC) Meso Scale Discovery (MSD) 3 plex assay (Wu-1 full-length spike, receptor binding domain (RBD), and N proteins). Wu-1 full-length spike and RBD were used to assess vaccine response. For concentrations below the lower limit of detection (LLOD), numeric values equivalent to LLOD/2 were assigned; concentrations above the upper limit of quantification were reported without adjustments. Antibody results collected after a documented COVID-19 infection, monoclonal antibody use, or a COVID-19 vaccine given off-study were excluded from the analyses. Participants with missing anti-COVID-19 antibody response data were considered to be missing-completely-at-random. |
| Secondary | Fold Inhibition of ACE2 Binding to SARS-CoV-2 Variant Antigens by Stage 1 Adult Samples | Week 0 and Weeks 4 and 12 Status Post Receipt of COVID-19 Vaccination | Antibody response was measured using the National Institute of Allergy and Infectious Disease Vaccine Research Center (NIAID-VRC) Meso Scale Discovery (MSD) V-Plex ACE2 neutralization assay which measure antibodies that block the binding of angiotensin-converting enzyme 2 (ACE2) to the SARS-CoV-2 Spike antigens, including variants of the SARS-CoV-2 virus according to the manufacturer's instruction (MSD Catalog # K15654U). Antibody results collected after a documented COVID-19 infection, monoclonal antibody use, or a COVID-19 vaccine given off-study were excluded from the analyses. Participants with missing anti-COVID-19 antibody response data were considered to be missing-completely-at-random. Results are reported as fold inhibition by a sample relative to signal from a 'diluent only' control (maximum ACE2 binding to antigen). Highly neutralizing samples show high fold inhibition whereas negative or low samples show low fold inhibition of ACE2 binding. |
1 to 10 of 58Source ClinicalTrials.gov
See all 58 registered outcomesOutcomes58
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Week 4 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were randomized or allocated and received study vaccine in the study. | Percentage of participants | NUMBER |
| PRIMARY | Percent of Stage 2 Adult Participants Who Have a Protective Antibody Response at Week 4 | Week 4 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were allocated and received study vaccine in the study. | Percentage of participants | NUMBER |
| PRIMARY | Percent of Stage 2 Pediatric Participants Who Have a Protective Antibody Response at Week 4 | Week 4 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were allocated and received study vaccine in the study. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Stage 1 Adult Participants Who Seroconverted | Week 4 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were randomized or allocated and received study vaccine in the study. Only participants who were anti-COVID-19 antibody negative (by either Wu-1 full-length spike or RBD) at Week 0 were included in the analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Stage 2 Adult Participants Who Seroconverted | Week 4 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were randomized or allocated and received study vaccine in the study. Only participants who were anti-COVID-19 antibody negative (by Wu-1 full-length spike or RBD) at Week 0 were included in the analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Fold Increase in Stage 1 Adult Anti-COVID-19 Antibody Levels | Week 4 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were randomized or allocated and received study vaccine in the study. Only participants who were anti-COVID-19 antibody positive (by Wu-1 full-length spike or RBD) at Week 0 were included in the analysis. | Fold Change | GEOMETRIC_MEAN |
| SECONDARY | Fold Increase in Stage 2 Adult Anti-COVID-19 Antibody Levels | Week 4 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were randomized or allocated and received study vaccine in the study. Only participants who were anti-COVID-19 antibody positive (by Wu-1 full-length spike or RBD) at Week 0 were included in the analysis. | Fold Change | GEOMETRIC_MEAN |
| SECONDARY | Change in Stage 1 Adult Anti-COVID-19 Antibody Response | Week 0 and Weeks 4 and 12 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were randomized or allocated and received study vaccine in the study. | IU/mL | GEOMETRIC_MEAN |
| SECONDARY | Change in Stage 2 Adult Anti-COVID-19 Antibody Response | Week 0 and Weeks 4 and 12 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were allocated and received study vaccine in the study. | IU/mL | GEOMETRIC_MEAN |
| SECONDARY | Fold Inhibition of ACE2 Binding to SARS-CoV-2 Variant Antigens by Stage 1 Adult Samples | Week 0 and Weeks 4 and 12 Status Post Receipt of COVID-19 Vaccination | The vaccinated population includes all participants who were randomized or allocated and received study vaccine in the study. | Fold Inhibition | GEOMETRIC_MEAN |
1 to 10 of 58Source ClinicalTrials.gov
See all 58 outcomesResults by group1,047
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants | |
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants | |
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort A, Arm A2: Pfizer-BioNTech + Continue IS (MMF or MPA) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants | |
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort A, Arm A5: Pfizer-BioNTech + Withhold IS (MMF or MPA) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants | |
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort A, Arm A6: Janssen + Withhold IS (MMF or MPA) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants | |
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants | |
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort B, Arm B4: Moderna mRNA-1273 + Withhold IS (MTX) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants | |
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort B, Arm B2: Pfizer-BioNTech + Continue IS (MTX) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants | |
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort B, Arm B5: Pfizer-BioNTech + Withhold IS (MTX) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants | |
| Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4 | Cohort C, Arm C1: Moderna mRNA-1273 + Continue IS (BCDT) | Week 4, Wu-1 Full-Length Spike | NA | Percentage of participants |
1 to 10 of 1,047Source ClinicalTrials.gov
See all 1,047 results by groupParticipant flow198
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Stage 1 | STARTED | Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA) | 2 | |
| Stage 1 | STARTED | Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA) | 2 | |
| Stage 1 | STARTED | Cohort A, Arm A2: Pfizer-BioNTech + Continue IS (MMF or MPA) | 9 | |
| Stage 1 | STARTED | Cohort A, Arm A5: Pfizer-BioNTech + Withhold IS (MMF or MPA) | 10 | |
| Stage 1 | STARTED | Cohort A, Arm A6: Janssen + Withhold IS (MMF or MPA) | 2 | |
| Stage 1 | STARTED | Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX) | 3 | |
| Stage 1 | STARTED | Cohort B, Arm B4: Moderna mRNA-1273 + Withhold IS (MTX) | 3 | |
| Stage 1 | STARTED | Cohort B, Arm B2: Pfizer-BioNTech + Continue IS (MTX) | 11 | |
| Stage 1 | STARTED | Cohort B, Arm B5: Pfizer-BioNTech + Withhold IS (MTX) | 11 | |
| Stage 1 | STARTED | Cohort C, Arm C1: Moderna mRNA-1273 + Continue IS (BCDT) | 41 |
1 to 10 of 198Source ClinicalTrials.gov
See all 198 participant flowAdverse events882
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Tachycardia | Cardiac disorders | Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA) | 0 | 2 | 0 |
| other | Tachycardia | Cardiac disorders | Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA) | 0 | 1 | 0 |
| other | Tachycardia | Cardiac disorders | Cohort A, Arm A2: Pfizer-BioNTech + Continue IS (MMF or MPA) | 1 | 8 | 1 |
| other | Tachycardia | Cardiac disorders | Cohort A, Arm A5: Pfizer-BioNTech + Withhold IS (MMF or MPA) | 0 | 9 | 0 |
| other | Tachycardia | Cardiac disorders | Cohort A, Arm A6: Janssen + Withhold IS (MMF or MPA) | 0 | 2 | 0 |
| other | Tachycardia | Cardiac disorders | Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX) | 0 | 3 | 0 |
| other | Tachycardia | Cardiac disorders | Cohort B, Arm B4: Moderna mRNA-1273 + Withhold IS (MTX) | 0 | 3 | 0 |
| other | Tachycardia | Cardiac disorders | Cohort B, Arm B2: Pfizer-BioNTech + Continue IS (MTX) | 0 | 10 | 0 |
| other | Tachycardia | Cardiac disorders | Cohort B, Arm B5: Pfizer-BioNTech + Withhold IS (MTX) | 0 | 10 | 0 |
| other | Tachycardia | Cardiac disorders | Cohort C, Arm C1: Moderna mRNA-1273 + Continue IS (BCDT) | 0 | 40 | 0 |
1 to 10 of 882Source ClinicalTrials.gov
See all 882 adverse eventsAdverse event totals63
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA) | 0 | 2 |
| Total, all-cause mortality | Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA) | 0 | 1 |
| Total, all-cause mortality | Cohort A, Arm A2: Pfizer-BioNTech + Continue IS (MMF or MPA) | 0 | 8 |
| Total, all-cause mortality | Cohort A, Arm A5: Pfizer-BioNTech + Withhold IS (MMF or MPA) | 0 | 9 |
| Total, all-cause mortality | Cohort A, Arm A6: Janssen + Withhold IS (MMF or MPA) | 0 | 2 |
| Total, all-cause mortality | Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX) | 0 | 3 |
| Total, all-cause mortality | Cohort B, Arm B4: Moderna mRNA-1273 + Withhold IS (MTX) | 0 | 3 |
| Total, all-cause mortality | Cohort B, Arm B2: Pfizer-BioNTech + Continue IS (MTX) | 0 | 10 |
| Total, all-cause mortality | Cohort B, Arm B5: Pfizer-BioNTech + Withhold IS (MTX) | 0 | 10 |
| Total, all-cause mortality | Cohort C, Arm C1: Moderna mRNA-1273 + Continue IS (BCDT) | 0 | 40 |
1 to 10 of 63Source ClinicalTrials.gov
See all 63 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41289027 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons5
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Grade 1 or Higher Adverse Events Related to Study Vaccine | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any New Onset Chronic Medical Conditions (NOCMCs) | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Medically Attended Adverse Events (MAAEs) | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Serious Adverse Events (SAEs) | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05000216
GET https://conductscience.org/api/trials/v1/NCT05000216/registered?page=2